# Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

> **NCT04361812** · PHASE1 · TERMINATED · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Similarity of Pharmacokinetics and Safety

## Interventions

- **DRUG:** HS632
- **DRUG:** Omalizumab (Xolair®)

## Key facts

- **NCT ID:** NCT04361812
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Company R\&D Strategy Adjustment
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361812, "Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04361812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*